Seroprevalence and burden of hepatitis C virus infection in WHO South‐East Asia Region: A systematic review
Background This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR). Methods Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non‐indexed national medical journals, government and i...
Gespeichert in:
| Veröffentlicht in: | Journal of gastroenterology and hepatology 2022-06, Vol.37 (6), p.964-972 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 972 |
|---|---|
| container_issue | 6 |
| container_start_page | 964 |
| container_title | Journal of gastroenterology and hepatology |
| container_volume | 37 |
| creator | Goel, Amit Rewari, Bharat Bhushan Sharma, Mukta Konath, Nabeel Mangadan Aggarwal, Rakesh |
| description | Background
This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR).
Methods
Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non‐indexed national medical journals, government and international health agencies were searched to identify English language literature published between 1991 and June 2020. We selected the studies reporting HCV seroprevalence in asymptomatic general (low‐risk) and high‐risk adult populations, that is, persons living with HIV (PLHIV), persons who inject drugs (PWID), sex workers, persons on maintenance hemodialysis (MHD), people in prison, and men sex with men (MSM). Seroprevalence data were combined to estimate weighted pooled prevalence (95% confidence interval) in each group and in each country, using the random‐effects model. Estimated pooled seroprevalences were multiplied with estimated populations at risk to estimate the overall HCV burden.
Results
The analysis included 538 studies (35 Bangladesh, 6 Bhutan, 2 DPR Korea, 323 India, 43 Indonesia, 2 Maldives, 18 Myanmar, 29 Nepal, 11 Sri Lanka, 67 Thailand, and 2 Timor‐Leste). In SEAR, the weighted pooled anti‐HCV seroprevalence was estimated as 0.84% (0.56–1.12) in low‐risk population and 13.67% (10.95–16.40) in PLHIV, 51.44% (43.67–59.20) in PWID, 25.80% (20.34–32.09) in MHD, 8.39% (5.84–11.51) in prison inmates, 2.69% (1.43–4.13) in people with high‐risk sex behavior, and 11.43% (8.61–14.74) in MSM. The total HCV burden in low‐risk and high‐risk populations in SEAR countries was estimated as 12.45 million and 1.65 million, respectively.
Conclusion
Our estimates of HCV seroprevalence and burden should help the respective countries in planning their HCV elimination strategies. |
| doi_str_mv | 10.1111/jgh.15827 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2676447520</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2676447520</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3537-d3fc328068cf4305cc676f123430455f3823ec38d878d1109508bdba46ad12723</originalsourceid><addsrcrecordid>eNp1kM9OAjEQhxujEUQPvoBp4snDQv9uizdCEDQkJqLxuOl2u1ACu9juQrj5CD6jT2J10ZtzmZnMl2-SHwCXGHVxqN5yvuhiLok4Am3MGIqwYPExaCOJedSnuN8CZ94vEUIMCX4KWpSTmEok2mA9M67cOLNVK1NoA1WRwbR2mSlgmcOF2ajKVtbDIdxaV3toi9zoypZFmODr5BHOyrpafL5_jJSv4MBbBZ_MPNxv4QD6va_MOhg0DB-s2Z2Dk1ytvLk49A54uRs9DyfR9HF8PxxMI005FVFGc02JRLHUOaOIax2LOMeEhoVxnlNJqNFUZlLIDGPU50imWapYrDJMBKEdcN14N658q42vkmVZuyK8TEhQMSY4QYG6aSjtSu-dyZONs2vl9glGyXewSQg2-Qk2sFcHY52uTfZH_iYZgF4D7OzK7P83JQ_jSaP8AtBkga8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676447520</pqid></control><display><type>article</type><title>Seroprevalence and burden of hepatitis C virus infection in WHO South‐East Asia Region: A systematic review</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Goel, Amit ; Rewari, Bharat Bhushan ; Sharma, Mukta ; Konath, Nabeel Mangadan ; Aggarwal, Rakesh</creator><creatorcontrib>Goel, Amit ; Rewari, Bharat Bhushan ; Sharma, Mukta ; Konath, Nabeel Mangadan ; Aggarwal, Rakesh</creatorcontrib><description>Background
This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR).
Methods
Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non‐indexed national medical journals, government and international health agencies were searched to identify English language literature published between 1991 and June 2020. We selected the studies reporting HCV seroprevalence in asymptomatic general (low‐risk) and high‐risk adult populations, that is, persons living with HIV (PLHIV), persons who inject drugs (PWID), sex workers, persons on maintenance hemodialysis (MHD), people in prison, and men sex with men (MSM). Seroprevalence data were combined to estimate weighted pooled prevalence (95% confidence interval) in each group and in each country, using the random‐effects model. Estimated pooled seroprevalences were multiplied with estimated populations at risk to estimate the overall HCV burden.
Results
The analysis included 538 studies (35 Bangladesh, 6 Bhutan, 2 DPR Korea, 323 India, 43 Indonesia, 2 Maldives, 18 Myanmar, 29 Nepal, 11 Sri Lanka, 67 Thailand, and 2 Timor‐Leste). In SEAR, the weighted pooled anti‐HCV seroprevalence was estimated as 0.84% (0.56–1.12) in low‐risk population and 13.67% (10.95–16.40) in PLHIV, 51.44% (43.67–59.20) in PWID, 25.80% (20.34–32.09) in MHD, 8.39% (5.84–11.51) in prison inmates, 2.69% (1.43–4.13) in people with high‐risk sex behavior, and 11.43% (8.61–14.74) in MSM. The total HCV burden in low‐risk and high‐risk populations in SEAR countries was estimated as 12.45 million and 1.65 million, respectively.
Conclusion
Our estimates of HCV seroprevalence and burden should help the respective countries in planning their HCV elimination strategies.</description><identifier>ISSN: 0815-9319</identifier><identifier>EISSN: 1440-1746</identifier><identifier>DOI: 10.1111/jgh.15827</identifier><identifier>PMID: 35263807</identifier><language>eng</language><publisher>Australia: Wiley Subscription Services, Inc</publisher><subject>Asia, Eastern ; disease burden ; Drug Users ; Hemodialysis ; Hepacivirus ; Hepatitis C ; Hepatitis C - epidemiology ; Hepatitis C virus ; hepatocellular carcinoma ; high risk behavior ; HIV ; HIV Infections - epidemiology ; Homosexuality, Male ; Human immunodeficiency virus ; Humans ; Male ; people living with HIV ; people who inject drugs ; Prevalence ; prison inmates ; Risk Factors ; Seroepidemiologic Studies ; Serology ; Sexual and Gender Minorities ; South East Asia region ; Substance Abuse, Intravenous - epidemiology ; Systematic review ; transfusion transmitted infections ; World Health Organization</subject><ispartof>Journal of gastroenterology and hepatology, 2022-06, Vol.37 (6), p.964-972</ispartof><rights>2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd</rights><rights>2022 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3537-d3fc328068cf4305cc676f123430455f3823ec38d878d1109508bdba46ad12723</citedby><cites>FETCH-LOGICAL-c3537-d3fc328068cf4305cc676f123430455f3823ec38d878d1109508bdba46ad12723</cites><orcidid>0000-0003-3525-9381 ; 0000-0001-9689-494X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjgh.15827$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjgh.15827$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35263807$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Goel, Amit</creatorcontrib><creatorcontrib>Rewari, Bharat Bhushan</creatorcontrib><creatorcontrib>Sharma, Mukta</creatorcontrib><creatorcontrib>Konath, Nabeel Mangadan</creatorcontrib><creatorcontrib>Aggarwal, Rakesh</creatorcontrib><title>Seroprevalence and burden of hepatitis C virus infection in WHO South‐East Asia Region: A systematic review</title><title>Journal of gastroenterology and hepatology</title><addtitle>J Gastroenterol Hepatol</addtitle><description>Background
This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR).
Methods
Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non‐indexed national medical journals, government and international health agencies were searched to identify English language literature published between 1991 and June 2020. We selected the studies reporting HCV seroprevalence in asymptomatic general (low‐risk) and high‐risk adult populations, that is, persons living with HIV (PLHIV), persons who inject drugs (PWID), sex workers, persons on maintenance hemodialysis (MHD), people in prison, and men sex with men (MSM). Seroprevalence data were combined to estimate weighted pooled prevalence (95% confidence interval) in each group and in each country, using the random‐effects model. Estimated pooled seroprevalences were multiplied with estimated populations at risk to estimate the overall HCV burden.
Results
The analysis included 538 studies (35 Bangladesh, 6 Bhutan, 2 DPR Korea, 323 India, 43 Indonesia, 2 Maldives, 18 Myanmar, 29 Nepal, 11 Sri Lanka, 67 Thailand, and 2 Timor‐Leste). In SEAR, the weighted pooled anti‐HCV seroprevalence was estimated as 0.84% (0.56–1.12) in low‐risk population and 13.67% (10.95–16.40) in PLHIV, 51.44% (43.67–59.20) in PWID, 25.80% (20.34–32.09) in MHD, 8.39% (5.84–11.51) in prison inmates, 2.69% (1.43–4.13) in people with high‐risk sex behavior, and 11.43% (8.61–14.74) in MSM. The total HCV burden in low‐risk and high‐risk populations in SEAR countries was estimated as 12.45 million and 1.65 million, respectively.
Conclusion
Our estimates of HCV seroprevalence and burden should help the respective countries in planning their HCV elimination strategies.</description><subject>Asia, Eastern</subject><subject>disease burden</subject><subject>Drug Users</subject><subject>Hemodialysis</subject><subject>Hepacivirus</subject><subject>Hepatitis C</subject><subject>Hepatitis C - epidemiology</subject><subject>Hepatitis C virus</subject><subject>hepatocellular carcinoma</subject><subject>high risk behavior</subject><subject>HIV</subject><subject>HIV Infections - epidemiology</subject><subject>Homosexuality, Male</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Male</subject><subject>people living with HIV</subject><subject>people who inject drugs</subject><subject>Prevalence</subject><subject>prison inmates</subject><subject>Risk Factors</subject><subject>Seroepidemiologic Studies</subject><subject>Serology</subject><subject>Sexual and Gender Minorities</subject><subject>South East Asia region</subject><subject>Substance Abuse, Intravenous - epidemiology</subject><subject>Systematic review</subject><subject>transfusion transmitted infections</subject><subject>World Health Organization</subject><issn>0815-9319</issn><issn>1440-1746</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM9OAjEQhxujEUQPvoBp4snDQv9uizdCEDQkJqLxuOl2u1ACu9juQrj5CD6jT2J10ZtzmZnMl2-SHwCXGHVxqN5yvuhiLok4Am3MGIqwYPExaCOJedSnuN8CZ94vEUIMCX4KWpSTmEok2mA9M67cOLNVK1NoA1WRwbR2mSlgmcOF2ajKVtbDIdxaV3toi9zoypZFmODr5BHOyrpafL5_jJSv4MBbBZ_MPNxv4QD6va_MOhg0DB-s2Z2Dk1ytvLk49A54uRs9DyfR9HF8PxxMI005FVFGc02JRLHUOaOIax2LOMeEhoVxnlNJqNFUZlLIDGPU50imWapYrDJMBKEdcN14N658q42vkmVZuyK8TEhQMSY4QYG6aSjtSu-dyZONs2vl9glGyXewSQg2-Qk2sFcHY52uTfZH_iYZgF4D7OzK7P83JQ_jSaP8AtBkga8</recordid><startdate>202206</startdate><enddate>202206</enddate><creator>Goel, Amit</creator><creator>Rewari, Bharat Bhushan</creator><creator>Sharma, Mukta</creator><creator>Konath, Nabeel Mangadan</creator><creator>Aggarwal, Rakesh</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope><orcidid>https://orcid.org/0000-0003-3525-9381</orcidid><orcidid>https://orcid.org/0000-0001-9689-494X</orcidid></search><sort><creationdate>202206</creationdate><title>Seroprevalence and burden of hepatitis C virus infection in WHO South‐East Asia Region: A systematic review</title><author>Goel, Amit ; Rewari, Bharat Bhushan ; Sharma, Mukta ; Konath, Nabeel Mangadan ; Aggarwal, Rakesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3537-d3fc328068cf4305cc676f123430455f3823ec38d878d1109508bdba46ad12723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Asia, Eastern</topic><topic>disease burden</topic><topic>Drug Users</topic><topic>Hemodialysis</topic><topic>Hepacivirus</topic><topic>Hepatitis C</topic><topic>Hepatitis C - epidemiology</topic><topic>Hepatitis C virus</topic><topic>hepatocellular carcinoma</topic><topic>high risk behavior</topic><topic>HIV</topic><topic>HIV Infections - epidemiology</topic><topic>Homosexuality, Male</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Male</topic><topic>people living with HIV</topic><topic>people who inject drugs</topic><topic>Prevalence</topic><topic>prison inmates</topic><topic>Risk Factors</topic><topic>Seroepidemiologic Studies</topic><topic>Serology</topic><topic>Sexual and Gender Minorities</topic><topic>South East Asia region</topic><topic>Substance Abuse, Intravenous - epidemiology</topic><topic>Systematic review</topic><topic>transfusion transmitted infections</topic><topic>World Health Organization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Goel, Amit</creatorcontrib><creatorcontrib>Rewari, Bharat Bhushan</creatorcontrib><creatorcontrib>Sharma, Mukta</creatorcontrib><creatorcontrib>Konath, Nabeel Mangadan</creatorcontrib><creatorcontrib>Aggarwal, Rakesh</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of gastroenterology and hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Goel, Amit</au><au>Rewari, Bharat Bhushan</au><au>Sharma, Mukta</au><au>Konath, Nabeel Mangadan</au><au>Aggarwal, Rakesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Seroprevalence and burden of hepatitis C virus infection in WHO South‐East Asia Region: A systematic review</atitle><jtitle>Journal of gastroenterology and hepatology</jtitle><addtitle>J Gastroenterol Hepatol</addtitle><date>2022-06</date><risdate>2022</risdate><volume>37</volume><issue>6</issue><spage>964</spage><epage>972</epage><pages>964-972</pages><issn>0815-9319</issn><eissn>1440-1746</eissn><abstract>Background
This systematic review was aimed to estimate hepatitis C virus (HCV) seroprevalence and burden in disease in WHO South East Asia Region (SEAR).
Methods
Electronic databases (PubMed, Scopus, Embase, and Google Scholar) and websites of non‐indexed national medical journals, government and international health agencies were searched to identify English language literature published between 1991 and June 2020. We selected the studies reporting HCV seroprevalence in asymptomatic general (low‐risk) and high‐risk adult populations, that is, persons living with HIV (PLHIV), persons who inject drugs (PWID), sex workers, persons on maintenance hemodialysis (MHD), people in prison, and men sex with men (MSM). Seroprevalence data were combined to estimate weighted pooled prevalence (95% confidence interval) in each group and in each country, using the random‐effects model. Estimated pooled seroprevalences were multiplied with estimated populations at risk to estimate the overall HCV burden.
Results
The analysis included 538 studies (35 Bangladesh, 6 Bhutan, 2 DPR Korea, 323 India, 43 Indonesia, 2 Maldives, 18 Myanmar, 29 Nepal, 11 Sri Lanka, 67 Thailand, and 2 Timor‐Leste). In SEAR, the weighted pooled anti‐HCV seroprevalence was estimated as 0.84% (0.56–1.12) in low‐risk population and 13.67% (10.95–16.40) in PLHIV, 51.44% (43.67–59.20) in PWID, 25.80% (20.34–32.09) in MHD, 8.39% (5.84–11.51) in prison inmates, 2.69% (1.43–4.13) in people with high‐risk sex behavior, and 11.43% (8.61–14.74) in MSM. The total HCV burden in low‐risk and high‐risk populations in SEAR countries was estimated as 12.45 million and 1.65 million, respectively.
Conclusion
Our estimates of HCV seroprevalence and burden should help the respective countries in planning their HCV elimination strategies.</abstract><cop>Australia</cop><pub>Wiley Subscription Services, Inc</pub><pmid>35263807</pmid><doi>10.1111/jgh.15827</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-3525-9381</orcidid><orcidid>https://orcid.org/0000-0001-9689-494X</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0815-9319 |
| ispartof | Journal of gastroenterology and hepatology, 2022-06, Vol.37 (6), p.964-972 |
| issn | 0815-9319 1440-1746 |
| language | eng |
| recordid | cdi_proquest_journals_2676447520 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Asia, Eastern disease burden Drug Users Hemodialysis Hepacivirus Hepatitis C Hepatitis C - epidemiology Hepatitis C virus hepatocellular carcinoma high risk behavior HIV HIV Infections - epidemiology Homosexuality, Male Human immunodeficiency virus Humans Male people living with HIV people who inject drugs Prevalence prison inmates Risk Factors Seroepidemiologic Studies Serology Sexual and Gender Minorities South East Asia region Substance Abuse, Intravenous - epidemiology Systematic review transfusion transmitted infections World Health Organization |
| title | Seroprevalence and burden of hepatitis C virus infection in WHO South‐East Asia Region: A systematic review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T20%3A40%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Seroprevalence%20and%20burden%20of%20hepatitis%20C%20virus%20infection%20in%20WHO%20South%E2%80%90East%20Asia%20Region:%20A%20systematic%20review&rft.jtitle=Journal%20of%20gastroenterology%20and%20hepatology&rft.au=Goel,%20Amit&rft.date=2022-06&rft.volume=37&rft.issue=6&rft.spage=964&rft.epage=972&rft.pages=964-972&rft.issn=0815-9319&rft.eissn=1440-1746&rft_id=info:doi/10.1111/jgh.15827&rft_dat=%3Cproquest_cross%3E2676447520%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2676447520&rft_id=info:pmid/35263807&rfr_iscdi=true |